In 2021, the International Neoadjuvant Melanoma Consortium reported the first pooled analysis from six clinical trials of anti-PD-1-based immunotherapy or BRAF/MEK-targeted therapy involving a total of 192 melanoma patients [81]. The gene discussed is MAP2K7; the disease is melanoma.